Ampliphi Biosciences Corp (NYSEMKT:APHB), which happen to be one of the most vibrant and trusted biotechnology companies majorly focusing on the development of to therapies for drug-resistant bacterial infections using bacteriophage technology, has today moved ahead to declare its position in regards to pricing.
The top provider reached the decision to actually announce the pricing of the underwritten public offering of about after a number of meetings which had the board members discuss the matter in an elaborate way.
According to sources close to the company, there will be an eventual decrease on a one-for one basis upon the prefunding of each and every warrant that the provider will be selling in terms of common stocks.
As a matter of fact, the common warrants will with immediate effect be exercisable at a price of about $1.50 per share of common stock and later on will eventually reach its expiry from the date from the day of issuance.
The pre-funded warrants or the shares of common stock, as well as the accompanying common warrants, can only be purchased together in the offering but will be channeled out separately. As a matter of fact, they will with immediate effect be separable upon issuance. According to some top trusted sources, the offering is set to close on or about May 10, 2017, which will of course be subject to the customary closing conditions.
While addressing a press conference, one of the company’s top executives revealed that indeed AmpliPhi had moved ahead to grant to the underwriter a 30-day option to complete the purchase of up to an extra of 1,043,478 shares of common stock.
That would then be channeled in the purchase of up to 1,043,478 shares of common stock of AmpliPhi, which was as a matter of fact to go at some set public offering price less commissions and discounts as well.
Sources indicate that the net proceeds arising from the dealing amount to about $9.8 million, and that is of course after making the associated deductions such as the underwriting commissions and discounts as well.